myeloma therapy. For patients younger than 65-75 years of age and older patients with good general health and no comorbid conditions, high-intensity chemotherapy with autologous hematopoietic cell transplantation is the standard treatment (10, 12) .
For patients who are not considered to be candidates for a high-dose chemotherapy regimen with or without transplantation, because of age or having a comorbidity, melphalan plus prednisone (MP) has been the standard treatment for more than 40 years (10, 12, 13) . In addition, there were several further regimens, for example, dexamethasone alone, thalidomide plus dexamethasone, vincristine plus doxorubicin and dexamethasone (12) , which also have been recommended as alternative treatments for these patients. However, in recent years, two treatment approaches-MP plus thalidomide (14, 15) and MP plus bortezomib (16) -have demonstrated improved antimyeloma, and the study showed and improved overall survival (OS) efficacy compared with MP alone. Both regimens are recommended by clinical guidelines as standard of care for the treatment of patients with MM who are ineligible for transplantation (10, 12, 13) . Another recommended treatment option is low-dose dexamethasone plus lenalidomide, which demonstrated improved complete response (CR) and overall response rates (ORRs) compared with high-dose dexamethasone plus lenalidomide (10, 12, 13, 17) . Below, we discuss currently published trials that examined different treatment approaches of lenalidomide, bortezomib, and thalidomide. 
Contribution.
The study enrolled 198 patients and did not reach the projected enrollment of 500 patients because the Data and Safety Monitoring Committee recommended early study closure. The trial included newly diagnosed, transplantation-ineligible and transplantation-denying adult patients with symptomatic MM. Patients were randomly assigned to three courses of lenalidomide plus dexamethasone (LD) or three courses of dexamethasone plus placebo (D) and were administered maintenance therapy with LD or D, respectively. Patients with progressive disease were encouraged to crossover from D to LD. Patients with progressive disease in the LD arm were removed from the study protocol.
The study protocol was amended after the first 21 patients were randomly assigned to a treatment arm because a statistically significant incidence of thromboembolic events in the LD arm was observed (eight of 12 patients receiving LD had thromboembolic events vs 0 of nine patients receiving D, P = .002). All subsequently randomly assigned patients received aspirin prophylaxis, but the excess of thromboembolic events in patients receiving LD persisted until the early closure or the trial (thromboembolic events were observed in 18 (19%) of 97 patients in the LD arm vs six (6%) of 95 patients in the D arm, P = .01).
The median follow-up time was not reported. Patients treated with LD had a statistically significantly increased ORR (LD arm ORR = 78% vs D arm ORR = 48%, P < .0001) and progression-free survival (PFS) (hazard ratio [HR] or P value not provided) compared with the patients in the D arm. However, the increased ORR and PFS among patients in the LD arm did not lead to improved OS, and a higher frequency of severe adverse events was observed in these patients.
Implication for Practice.
Both the early closure of a study and crossover among patients into a different study arm may cause severe bias in treatment outcomes. Therefore, outcomes in this study should be interpreted very carefully because of methodological shortcomings. An alarming incidence of thromboembolic events led to the recommendation of administration of a general thromboprophylaxis to patients. Although the results of this trial indicated improved ORR and PFS for patients receiving LD, the treatment was also associated with a higher frequency of severe adverse events, particularly, neutropenia, lymphocytopenia, infections, and thromboembolic events. The value of LD regarding OS remains unclear because of the high number of patients who crossed over from D to LD.
Most Interesting Feature.
This trial was closed early because of the high incidence of thromboembolic events in the LD arm. This statistically significantly higher incidence of these events persisted after the amendment of the protocol, which recommended aspirin prophylaxis for all patients. *CR = complete response; D = high-dose dexamethasone (study arm 2); LD = lenalidomide and high-dose dexamethasone (study arm 1); PD = progressive disease; PFS = progression-free survival; PR = partial response; OS = overall survival; ORR = overall response rate. †Six patients were ineligible: three patients did not meet baseline disease characteristics, two patients had inadequate organ function, and one patient had a prior malignancy. 
Contribution.
This randomized, multicenter open-label trial enrolled 260 patients. It included previously untreated adult MM patients aged 65 years or older. The trial examines the efficacy and safety of bortezomib plus thalidomide and prednisone (VTP, n = 130) compared with bortezomib plus melphalan and prednisone (VMP, n = 130). Patients who completed the induction therapy were subsequently randomly assigned to 3-year maintenance therapy with either bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP). Bortezomib was mainly administered once a week rather than twice a week, as it was done by San Miguel et al. (16) . Furthermore, the number of induction therapy cycles was reduced from nine to six (16) . This less-intensive bortezomib regimen was given in both arms of the trial.
After a median follow-up of 32 months after patients were randomly assigned to induction therapy, CR, ORR, PFS, and OS were similar for both induction treatment arms. Regarding adverse events, treatment with VTP caused a statistically significantly increased number of serious adverse events (SAEs) and discontinuations because of SAEs compared with treatment with VMP.
After induction therapy, 178 patients were randomly assigned to receive VT (n = 91) or VP (n = 87) as maintenance therapy. CR, PFS, OS, severe adverse events, discontinuation of treatment because of adverse events, and the number of deaths were similar in the VT and VP maintenance therapy arms. Mateos et al. (3) concluded that the outcome of VT maintenance was independent of the type of induction therapy administered. Further data of subgroup analyses were not provided.
Implication for Practice.
The aim of this study was to investigate if administration of less-intensive bortezomib could maintain efficacy and reduce the toxic effects. Therefore, the frequency of bortezomib administration and the total number of induction therapy cycles was reduced.
Mateos et al. (3) investigated VT compared with VMP. It was powered to investigate efficacy by measuring CR. However, results are similar in terms of PFS and OS, but this cannot be interpreted as proven similar efficacy of both treatments. These results might have been caused by the small number of patients (n = 260) and/or a small number of observed events (number of events regarding PFS or OS were not reported). Furthermore, VTP showed an increased number of SAEs and discontinuations because of SAEs. Regarding maintenance therapy, the comparison of VT and VP did not show any advantages or disadvantages of one treatment vs the other.
Most Interesting Feature.
The trial investigated two less-intensive VTP regimens in elderly untreated patients with MM but did not provide a direct comparison with the effective VTP regimen that was investigated by San Miguel et al. (16) . Further studies designed to examine differences in PFS and OS are needed to clarify the efficacy of VTP compared with VMP. Sample size (n = 260) was determine by a calculation for two randomizations; First randomization for induction therapy was aimed to achieve 20% difference in the CR rate after induction; Second randomization for maintenance therapy was aimed to improve the CR rate by ≥15% after maintenance.
Randomization
Generation of allocation sequences was done by a computerized random number generator (randomization was communicated via a web-based registration)
Blinding Open label, with no blinding of the participants those giving treatment, assessing outcomes, or analyzing data. 2, 95% CI = 0.9 to 1.7; P = .1); The PFS for maintenance therapy was similar between the two arms (HR = 1.4, 95% CI = 0.8 to 2.1; P = .1); The OS for induction therapy at 3 y was similar between the VMP (76%) and VTP (65%) arms (HR = 1.2, 95% CI = 0.7 to 1.9; P = .3); The OS for maintenance therapy between the two arms was similar (HR = 1.2, 95% CI = 0.6 to 2.4; P value not provided); Differences between the arms in safety outcomes during induction therapy: related SAEs = 15% for the VMP arm vs 31% for the VTP arm (P = .01), patients discontinuing because of SAEs = 12% for the VTP arm vs 17% for the VMP arm (P = .03), deaths = 5% for the VTP arm vs 5% for the VMP arm (P = .8); Differences in safety outcomes during maintenance therapy: patients discontinuing because of SAEs = 8% for the VT arm vs 5% for the VP arm (P = .6), deaths = 1% for the VT arm vs 1% for the VP arm (P = .8).
Potential conflicts of interest
Ten (including first, second, and last author) of the 29 authors declared conflicts of interest because they received honoraria from Celgene and OrthoBiotech or served on the speaker's bureau for Millennium, Celgene, and/or Ortho-Biotech. *HR = hazard ratio; MM = multiple myeloma; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; PR = partial response; SAE = serious adverse event; VP = bortezomib and prednisone; VT = bortezomib and thalidomide; VMP = bortezomib, melphalan, and prednisone; VTP = bortezomib, prednisonse, and thalidomide.
Trial 3: Melphalan and Prednisone Plus Thalidomide or Placebo in Elderly Patients With Multiple Myeloma
Waage A, Gimsing P, Fayers P, et al.; Nordic Myeloma Study Group. Blood. 2010;116(9):1405-1412 (2).
Contribution.
This trial enrolled 363 patients of the initially estimated 800. The reasons for under-recruiting were not provided. The study by Waage et al. (2) is a double-blind placebo-controlled trial that included newly diagnosed, transplantation-ineligible, or transplantation-denying adult patients with symptomatic MM. The patients were randomly assigned to receive either melphalanprednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MPP). After a median follow-up time of 42 months, patients showed no statistically significant difference in terms of OS and PFS between the treatment arms. Patients treated with MPT had two times more nonhematologic adverse events (40% patients in MPT arm vs 19% patient in MPP arm) and discontinued therapy more often because of adverse events (32% patients in MPT arm vs 10% patients in MPP arm). The median survival was not statistically significant shorter in the MPT arm with 29 months compared with 32 months in the MPP arm. Furthermore, the authors of the article discussed a slight, not statistically significant, increase in mortality of patients with thalidomide treatment within the first 6 months. In this period, there were 35 deaths in the MPT arm vs 21 deaths in the MPP arm. The main part of these patients was older than 75 years. In the MPT arm, 65% of patients who died in the first 6 months were at least 75 years old compared with 52% in the MPP arm. A similar effect was detectable in the results presented by Wijermans et al. (4) (publication discussed below). Quality of life was assessed at 3 and 12 months, but the provided data and results are not sufficient to validate the authors' conclusion.
Implication for Practice.
Administration of thalidomide in addition to MPP showed no statistically significant improvement compared with MP plus placebo in terms of OS, PFS, or quality of life. However, patients treated with MPT had two times more nonhematologic adverse events and discontinued therapy three times more often because of adverse events. Furthermore, patients older than 75 years of age might have an increased risk of early mortality when receiving MPT, which should be taken into consideration during individually adapted patient treatment.
Most Interesting Feature.
This trial and the study presented by Wijermans et al. (4) 
Results
OS was similar between MPT (median survival = 29 mo) and MPP arms (median survival = 32 mo), HR not reported, P = .16; PFS was similar between MPT (median survival = 15 mo) and MPP arms (median survival=14 mo), HR and P not reported; ORR: 57% MPT arm and 40% MPP arm; CR: 13% MPT arm and 4% MPP arm; PR: 34% MPT arm and 33% MPP arm; Health-related quality of life (QLQ-C30) was assessed at 3 mo (82% replied in the MPT and 90% in the MPP arm) and at 12 mo (50% replied in the MPT and 62% replied in the MPP arm). Quality of life was improved in both treatment arms after initiation of treatment. Besides a marked increase in constipation among patients in the MPT arm (P = .001), both arms are similar regarding assessed quality of life measures (the article did not provide data to verify these statements); Differences between the arms in safety outcomes (P values not provided): Cumulative rate of all nonhematologic AE = 40% for the MPT arm vs 19% for the MPP arm, discontinuations because of AE = 59 patients of the MPT arm vs 18 patients of the MPP arm, infections grade 3 or 4 = 15% for the MPT arm vs 10% for the MPP arm, cardiologic toxicity grade 3 or 4 = 7% for the MPT arm vs 5% for the MPP arm, non-neuropathy neurological toxicity grade 3 or 4 = 8% for the MPT arm vs 2% for the MPP arm, neuropathy grade 3 or 4 = 6% for the MPT arm vs 1% for the MPP arm, constipation grade 3 or 4 = 6% for the MPT arm vs 3% for the MPP arm, thromboembolic events grade 3 or 4 = 8% for the MPT arm vs 8% for the MPP arm.
Feature Details

Potential conflict of interest
Five of the 25 named authors (including the first and second authors) are consultants of at least one of the following companies: Janssen Cilag, GenMab, Schering-Plough, Bristol-Myers Squibb, Merck Serono. Another author was employed by Roche after the study was published.
Funding source
The trial was granted by the Norwegian Cancer Society and the Norwegian Research Council. Thalidomide and placebo were provided by Gruenenthal Gmbh, Aachen.
*CR = complete response; MPP = melphalan and placebo; MPT = melphalan and thalidomide; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; PR = partial response; WHO = World Health Organization. 
Contribution.
This was an open-label multicenter trial. It included newly diagnosed patients with MM older than 65 years of age. These were randomly assigned to eight cycles of melphalan 0.25 mg/kg and prednisone 1 mg/kg (which were administered daily for 5 days every 4 weeks) (MP, N = 173) or eight cycles of MP with thalidomide 200 mg/d (MPT, N = 171). Only patients in the MPT arm received maintenance therapy (thalidomide 50 mg/d, N = 65). That was administered until relapse. The trial was stopped after randomization of 344 patients instead of 420 estimated patients, because two other publications (14,15) indicated a superior effect of MPT compared with MP alone. Of these 344 patients, 11 were excluded because they did not comply with the entry criteria.
After a median follow-up of 39 months, patients with MPT showed a statistically significant improved PFS (multivariate regression analysis: HR = 0.65, 95% CI = 0.49 to 0.88; P = 0.006). There was no statistical difference in OS (multivariate regression analysis: HR = 0.82, 95% CI = 0.61 to 1.10; P = 0.19). Most interesting, the figure displaying the OS curve, only representing patients older than 75 years of age, suggests a slight increase in mortality in MPT arm during the first months. This was seen likewise for patients older than 75 years of age in the Waage et al. (2) trial (publication discussed above). As expected, MPT was less tolerated than MP (treatment discontinuations: 37% vs 10%; adverse events grade 3 or 4: 50% vs 29%, particularly neurological toxicities 23% vs 4% and thrombosis 3% vs 0%). Data regarding treatment-related mortality were not provided. According to the authors of the study, 285 of 333 eligible patients participated in the quality of life study that will be presented separately. So far, they state that there were no subscales indicating a favorable or unfavorable influence of thalidomide.
Implications for Practice.
This trial showed statistically significant improved PFS and response rates for patients receiving MPT compared with MP alone. This did not lead to a statistically significant improvement of OS. Furthermore, treatment with MPT caused more severe adverse events (P values not provided) and the discontinuation of treatment because of toxicity was four times more likely in patients receiving MPT compared with those in the MP arm. [Please consider a further discussion of these results stated above at "Most interesting feature" of Waage et al. (2) 
Contribution.
Bisphosphonates were developed mainly to impair malignant osteolysis; however, preclinical studies suggest that bisphosphonates might have inherent anticancer activities (18) . The study by Morgan et al. (5) was a randomized, open-label multicenter trial comparing two bisphosphonates, that is, clodronic acid (daily oral dose of 1600 mg) and zoledronic acid (4 g given intravenously every 3-4 weeks). The bisphosphonates were given in addition to intensive chemotherapy (ie, four to six 21-day cycles of cyclophosphamide, vincristine, doxorubicin, and dexamethasone or cyclophosphamide, thalidomide, and dexamethasone) or nonintensive chemotherapy (ie, six to nine 28-day cycles of MP or attenuated cyclophosmamide, thalidomide, and dexamethasone).
The trial enrolled 1970 adult patients with newly diagnosed MM. Of these patients, 1960 were eligible for intention-to-treat analysis. The zoledronic acid group (n = 981) included 555 patients receiving intensive chemotherapy and 426 patients receiving on nonintensive chemotherapy. The clodronic acid group (n = 979) included 556 patients receiving intensive chemotherapy and 423 patients receiving nonintensive chemotherapy. After induction therapy, 820 patients without progressive disease were randomized again to receive thalidomide or no further treatment as maintenance therapy. Both bisphosphonates and maintenance therapy were given continuously at least until disease progression. Mhaskar et al. (19) reported a systematic review with metaanalysis and indirect comparison that did not reveal the superiority of any particular type of bisphosphonate compared with others in terms of OS or PFS (19) . Despite the findings, patients of the study by Morgan et al. (5) treated with zoledronic acid showed statistically significantly increased PFS (median PFS = 19.5 months for zoledronic acid vs 17.5 months for clodronic acid, HR = 0.88, 95% CI = 0.80 to 0.98; P = .0179) and OS (median OS = 50.0 months for zoledronic acid vs 44.5 months for clodronic acid, HR = 0.84, 95% CI = 0.74 to 0.96; P = .0118) compared with patients receiving clodronic acid, after a median follow-up of 3.7 years. However, the direct comparison of the treatment with zoledronic acid caused a statistically significantly increase in the percentage of SAEs observed in patients given zoledronic acid (55%) vs clodronic acid (49%) (P < .0001), particularly thrombotic events (16% for zoldronic acid vs 12% for clodronic acid, P = .01) and osteonecrosis of the jaw (4% for zoledronic acid vs <1% for clodronic acid, P < .0001). Data regarding treatment-related mortality or results with respect to the different maintenance therapy approaches were not provided.
Implications for Practice.
This was an innovative RCT with newly diagnosed adult MM patients. It examined the anticancer properties of two bisphosphonates, clodronic acid and zoledronic acid, given in combination with intensive or nonintensive chemotherapy. It showed that zoledronic acid in addition to chemotherapy improved PSF and OS (extended median OS by approximately 5.5 months) compared with clodronic acid in addition to chemotherapy, but caused more SAEs, particularly thrombotic events, and osteonecrosis of the jaw. These findings support the hypothesis that zoledronic acid has anticancer activity in addition to the treatment benefits in bone health for patients with MM.
Other Interesting Trials Hodgkin lymphoma (HL) is a malignancy of the lymph nodes and lymphatic system with possible involvement of other organs. With an annual incidence of approximately 2-3 cancers per 100 000 inhabitants of Western countries, it is a comparatively rare disease, but it is one of the most common malignancies in young adults (20) . Between 80% and 90% of HL in adults can be cured by primary chemotherapy with or without radiotherapy (6, 21, 22) .
The study by Engert et al. (6) was a randomized, open-label multicenter trial that included 1370 newly diagnosed early-stage HL patients (clinical stage I or II). These were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups: group 1 received four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of involved-field radiation therapy (IFRT) (n = 346); group 2 received four cycles of ABVD followed by 20 Gy of IFRT (n = 340); group 3 received two cycles of ABVD followed by 30 Gy of IFRT (n = 341); and group 4 received two cycles of ABVD followed by 20 Gy of IFRT (n = 343). After a median follow-up period of 7.5 years, different cycles of administrated chemotherapy regimens (two cycles of ABVD vs four cycles of ABVD) as well as the two doses of radiation therapy (20 Gy vs 30 Gy), freedom from treatment failure and OS were similar among the different treatment groups. Furthermore, patients who were in the most intense treatment arm of four cycles ABVD and 30 Gy IFRT had similar freedom from treatment failure (HR = 1.07, 95% CI = 0.65 to 1.77) and OS (HR = 0.85, 95% CI = 0.41 to 1.79) compared with the arm with least intense therapy of two cycles ABVD and 20 Gy IFRT. Adverse events occurred more often in patients receiving four cycles of ABVD than in those with two cycles of ABVD. These events include severe toxicity of grade III or IV (51.7% for patients receiving four cycles ABVD and 30 Gy IFRT vs 33.2% for patients receiving two cycles ABVD and 20 Gy IFRT; P < .001) and treatment-related deaths (six deaths vs one death, respectively). Furthermore, patients with the more intense therapy of 30 Gy of IFRT reported more SAEs (grade III or IV) than those who received 20 Gy (8.7% vs 2.9%, respectively; P < .001). However, the occurrence of secondary cancers among the four treatment groups, the pooled chemotherapy groups, or the pooled radiation therapy groups was similar (P = .59, .89, and .34, respectively). Data regarding further long-term toxicities such as infertility or cardiopulmonary diseases were not provided.
The results of Engert et al. (6) demonstrated that a reduced intensity of treatment with a short two-cycle chemotherapy treatment of ABVD followed by a reduced radiation of 20 Gy IFRT does not have a reduced ability to cure patients with early-stage HL. The side effects of this shorttime treatment are considerably lower, and the less-intensive approach might also lead to a reduction of treatment-induced late toxicities. Chronic lymphocytic leukemia accounts for 25% of all leukemia and is the most common lymphoid malignancy in Western hemisphere. The disease remains incurable with conventional chemotherapy. On the one hand, rituximab in addition to chemotherapy may be an effective treatment option for chronic lymphocytic leukemia patients with the potential of finally increasing overall survival. On the other hand, there is also a risk of serious side effects (eg, infections).
The randomized, open-label multicenter trial reported by Hallek et al. (8) enrolled 817 previously untreated patients with chronic lymphocytic leukemia (Binet stage C or active disease of Binet stages A or B). They were randomly assigned to six courses offludarabine at 25 mg/m 2 per day and cyclophosphamide at 250 mg/m 2 per day (FC, n = 409) or six courses of FC (the same schedule as the other arm) plus rituximab (375 mg/m 2 on day 0 of course 1, and 500 mg/m 2 on day 1 of courses 2-6) (FCR, n = 408).
Three years after patients were randomly assigned to treatment arms, those treated with FCR showed statistically significantly increased PFS (median = 51.8 months for the FCR arm vs 32.8 months for the FC arm, HR = 0.56, 95% CI = 0.46 to 0.69, P < .0001) and overall survival (the time to 25% of patients dying was 62.5 months for the FCR arm vs 46.8 months for the FC arm, HR = 0.67, 95% CI = 0.48 to 0.92, P = .01) compared with the FC arm. As expected, FCR was less tolerated than FC (grade 3 or 4 adverse events = 76% for the FCR arm vs 63% for the FC arm). This difference in tolerability was attributed to hematologic toxicities, particularly neutropenia (34% for the FCR arm vs 21% for the FC arm) and leucocytopenia (24% for the FCR arm vs 12% for the FC arm). However, treatment-related mortality was similar among the two treatment arms (eight patients in the FCR arm and 10 patients in the FCR arm died because of toxic effects).
The main limitation of this study relates to the study population examined in the trial. The median age of included patients was 61 years of age, which is substantially lower than that of the average population of patients with chronic lymphocytic leukemia, who have a median age at disease onset of about 70 years. Therefore, the authors conclude that the population in this trial represents a selection of fairly young and physically fit patients and, as a consequence, conclusions from this trial should not be generalized to physically unfit elderly patients with chronic lymphocytic leukemia.
The report by Hallek et al. (8) was the first RCT that demonstrated an improvement in OS for physically fit chronic lymphocytic leukemia patients receiving FCR as first-line therapy. Adverse events (particularly neutropenia and leucocytopenia) occurred more often when patients were treated with FCR compared with FC but did not result in an increase in the treatment-related mortality rate. Follicular lymphoma is the most common indolent and second most common non-Hodgkin lymphoma in the Western world. Prognosis and therapy of follicular lymphoma depends on the disease stage. Disseminated disease is usually incurable, whereas asymptomatic patients with no adverse prognostic features are initially only observed (watchful waiting). However, most of the diagnosed patients need systemic cytotoxic-based treatment, and their estimated median survival time is 8-10 years.
The study by Salles et al. (7) was a randomized, open-label, international multicenter trial that included 1019 adult patients with CR or partial response after first-line therapy with three different immunotherapy induction regimens (nonrandomized). Patients were randomly assigned to 2 years of rituximab maintenance therapy (375 mg/m² every 8 weeks, n = 505) or observation (n = 513). After a median follow-up of 36 months, PFS (beginning at the time of random assignment that was 6 months after the start of induction therapy) was assessed as the primary endpoint. A statistically significantly increase in PFS (HR = 0.55, 95% CI = 0.44 to 0.68, P <·.0001) was observed in patients receiving rituximab maintenance therapy (74.9%) vs observation (57.6%). During this period, less than 5% of patients in each group had died, and OS was similar between the two treatment arms (HR = 0.87, 95% CI = 0.51 to 1.47). As expected, rituximab maintenance therapy led to more grade 3 or 4 adverse events than observation (24% vs 17%, respectively). Most grade 3 or 4 side effects occurring in the rituximab maintenance arm were neutropenia (4% for the rituximab arm vs 1% for the observation arm), neoplasia (4% for the rituximab arm vs 3% for the observation arm), and infections (4% for the rituximab arm vs 1% for the observation arm). Altogether, one patient died of toxic effects after maintenance treatment with rituximab.
The RCT by Salles et al. (7) found that rituximab maintenance therapy improves PFS in patients with follicular lymphoma who respond to a combination of chemotherapy plus rituximab administered as first-line treatment. To date, no benefit in OS has been reported and longer follow-up is needed to investigate the impact of rituximab maintenance therapy on OS.
New Reviews and Protocols in the Cochrane Library
In the latest issues of the Cochrane Library (Issue 6, 2010-Issue 2, 2011; see www.thecochranelibrary.com), two new reviews, one review update, and eight new protocols were published. 
Clinical Background.
Myelodysplastic syndromes, a heterogeneous group of disorders, are characterized by myeloid and/or erythroid, and/or megakaryocytic dysplasia and is associated with ineffective hematopoiesis and a high rate (~70%) of transformation to acute myeloid leukemia. In the general population, myelodysplastic syndromes are rare with an incidence of approximately 5 cancers per 100 000 people. This rate increases with age (50 cancers per 100 000 people for those older than 70 years) (24) . Because of symptomatic anemia, most patients require supportive therapy including repeated red blood cell transfusions, which cause the accumulation of iron (25) . An iron overload is associated with the risk of organ dysfunction and reduced life expectancy (26) . Iron chelation therapy is typically used to avoid an iron overload because the human body has no natural means of discarding it. The conclusion of Meerpohl et al. (23) is that it is unclear whether the new oral chelator deferasirox leads to a clinical benefit in patients with high iron levels.
Contribution.
Meerpohl et al. (23) searched different databases for RCTs examining deferasirox compared with no therapy, placebo, or another iron chelating treatment schedule. To date, the authors have identified only one ongoing study comparing deferasirox with deferoxamine for inclusion in their review; therefore, data are not currently available.
Implications for Practice.
Meerpohl et al. (23) conclude that recommendations about the consideration of iron chelation therapy for low-risk myelodysplastic syndromes cannot be supported by high-quality data from RCTs at this time. Therefore, data from the ongoing trial are urgently needed to warrant the widespread use of deferasirox outside clinical studies. However, in the interval, the decision to use deferasirox for individual patients should be on the basis of personal preferences considering potential benefits as well as harms. 
Clinical Background.
HL is a malignancy of the lymphatic system that can occur in children and adults, but it is more common in the third decade of life. It is one of the most curable forms of cancer. Generally, the disease is differentiated into early-stage and advanced-stage HL. The review by Herbst et al. (27) focuses on the therapy options of early-stage HL. Although both chemotherapy alone and combined chemotherapy plus radiotherapy are effective for the treatment of early-stage HL, the optimal choice of treatment for these patients is discussed.
Contribution.
The review by Herbst et al. (27) includes 1245 patients from five trials in the main analysis and found that the addition of radiotherapy to six cycles of chemotherapy is a better treatment option than six cycles of the same chemotherapy alone in patients with early-stage HL. The metaanalysis showed statistically significantly increased to OS (HR = 0.40, 95% CI = 0.27 to 0.61); number needed to treat is 11 to 55 patients depending on risk of death and tumor control (HR = 0.41, 95% CI = 0.25 to 0.66); the number needed to treat is five patients. CR and ORR were similar among the two treatment arms. Both chemotherapy alone and combined modality treatment seem to be effective in the short term. Differences in outcomes between the two treatment arms emerged when patients were followed up for several years (the median follow-up period of the studies ranged between 22 months and 11 years). Furthermore, the rate of adverse events was also similar between the treatment arms, although only one trial reported secondary malignancies. Because adding radiotherapy may result in more secondary malignancies, or cardiac disease and deaths, long-term follow-up (>15 years) of clinical trials examining treatment options in early-stage HL should be performed.
Limitations of the review by Herbst et al. (27) include that inconsistencies among the five trials used for analysis may be caused by different chemotherapy regimens, but the summarized hazard ratios in the subgroup analyses by chemotherapy regimens were similar. Another potential limitation might be that the trials used different radiotherapy fields (involved field was used in three trials and extended field was used in two trials), but no difference in OS was observed between trials that examined the addition of involved-field or extended-field radiotherapy.
Implications for Practice.
The authors conclude that the currently available evidence suggests that patients should not avoid additional radiotherapy. Chemotherapy plus radiotherapy is superior to the identical chemotherapy administered alone in patients with early-stage HL in terms of rates of death and tumor relapse.
New Protocols
Cochrane reviews published eight new protocols.
Protocol 1
The first protocol by Martí-Carvajal et al. (28) entitled "Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia" assessed the clinical effectiveness and safety of pharmacological interventions such as heparins (low-molecular weight heparin and unfractionated heparin), danaparoid sodium, synthetic protease inhibitor with antithrombin, human recombinant activated protein C, recombinant human soluble thrombomodulin, recombinant tissue factor pathway inhibitor, recombinant activated factor VIIa, and recombinant hirudin with antifibrinolytic drugs for treating disseminated intravascular coagulation in patients with acute or chronic leukemia.
Protocol 2
The second protocol by Pidala et al. (29) entitled "Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia (ALL) in first complete remission" provided evidence of the affectivity of a sibling donor allocated to allogeneic hematopoietic cell transplantation compared with those without a sibling donor who were assigned to nonallogeneic hematopoietic cell transplantation therapy. The review will assess OS, PFS, relapse, treatment-related mortality, quality of life, and adverse events.
Protocol 3
The third protocol by Franklin et al. (30) entitled "Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival" compared the risks of secondary malignant neoplasms including secondary solid tumors, secondary NHL, and secondary AML in HL patients according to the design of first-line treatment, which includes use of chemotherapy, radiotherapy, or both, type and amount of chemotherapy, and the extent and dosage of radiation.
Protocol 4
The fourth protocol by Schlaak et al. (31) entitled "Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T cell lymphoma" assessed OS, PFS, relapse, treatment-related mortality, quality of life, and adverse events after allogeneic stem cell transplantation compared with conventional therapy.
Protocol 5
The fifth protocol by Itchaki et al. (32) entitled "Anthracyclines-containing regimens for treatment of follicular lymphoma in adults" evaluated OS, PFS, CR, ORR, response duration, relapse, quality of life, and adverse events after anthracycline-containing regimens with or without radiotherapy compared with non-anthracycline-containing regimens.
Protocol 6
The sixth protocol by Ossendorf et al. (33) , "Idiotype vaccination for Non-Hodgkin lymphoma" evaluated the therapeutic benefit of idiotype vaccination compared with no further treatment by measuring OS, PFS, response rate, treatment-related mortality, adverse events, and quality of life.
Protocol 7
The seventh protocol by Zeng et al. (34) entitled "Pegylated liposomal doxorubicin for multiple myeloma" assessed the effectiveness of pegylated liposomal doxorubicin vs placebo, no treatment, or another active agent with respect to OS, PFS, time to progression, very good partial response, adverse events, and quality of life.
Protocol 8
The eighth protocol by Wheatley et al. (35) entitled "Thalidomide, lenalidomide and their analogues, as therapy for multiple myeloma" evaluated thalidomide and other immunomodulatory drugs compared with placebo or no treatment, or other active treatment with respect to OS, PFS, time to progression, CR, partial response, adverse events, and quality of life.
